Hangzhou Bio-Sincerity Pharma-Tech Co (SZSE:301096) COGS-to-Revenue : 0.32 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Hangzhou Bio-Sincerity Pharma-Tech Co COGS-to-Revenue?

Hangzhou Bio-Sincerity Pharma-Tech Co's Cost of Goods Sold for the three months ended in Mar. 2024 was ¥69 Mil. Its Revenue for the three months ended in Mar. 2024 was ¥216 Mil.

Hangzhou Bio-Sincerity Pharma-Tech Co's COGS to Revenue for the three months ended in Mar. 2024 was 0.32.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Hangzhou Bio-Sincerity Pharma-Tech Co's Gross Margin % for the three months ended in Mar. 2024 was 68.19%.

Hangzhou Bio-Sincerity Pharma-Tech Co COGS-to-Revenue Historical Data

The historical data trend for Hangzhou Bio-Sincerity Pharma-Tech Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hangzhou Bio-Sincerity Pharma-Tech Co COGS-to-Revenue Chart

Hangzhou Bio-Sincerity Pharma-Tech Co Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.38

0.34

0.33

0.34

Hangzhou Bio-Sincerity Pharma-Tech Co Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.34	0.33	0.32	0.39	0.32

Hangzhou Bio-Sincerity Pharma-Tech Co COGS-to-Revenue Calculation

Hangzhou Bio-Sincerity Pharma-Tech Co's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	350.737	/	1017.448
	=	0.34

Hangzhou Bio-Sincerity Pharma-Tech Co's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	68.611	/	215.703
	=	0.32

Hangzhou Bio-Sincerity Pharma-Tech Co (SZSE:301096) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Hangzhou Bio-Sincerity Pharma-Tech Co's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	68.611 / 215.703
	=	68.19 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Hangzhou Bio-Sincerity Pharma-Tech Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Hangzhou Bio-Sincerity Pharma-Tech Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Hangzhou Bio-Sincerity Pharma-Tech Co (SZSE:301096) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hangzhou Bio-Sincerity Pharma-Tech Co Ltd (SZSE:301096) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

611 Dongguan Road, 2nd Floor, Building 8, Jinsheng Technology Park, Binjiang District, Hangzhou, CHN

Website

https://www.hzbio-s.com

Hangzhou Bio-Sincerity Pharma-Tech Co Ltd is a pharmaceutical technology research and development company. The company's business covers drug discovery, pharmaceutical research, clinical research, and registration application.

Hangzhou Bio-Sincerity Pharma-Tech Co (SZSE:301096) Headlines

No Headlines